2005-04-25

and CTLA-4 checkpoint pathways while also providing PD-L1-dependent CD28 costimulation, as intentionally designed. A second poster demonstrated the ability of ALPN-202 to improve significantly upon the activity of existing cancer therapeutics when given alone and/or in … ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download